PMID- 20130440
OWN - NLM
STAT- MEDLINE
DCOM- 20100323
LR  - 20151119
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Linking)
VI  - 77 Suppl 1
DP  - 2009
TI  - Targeted therapy in the treatment of metastatic renal cell cancer.
PG  - 122-31
LID - 10.1159/000258504 [doi]
AB  - The treatment of metastatic renal cell carcinoma (MRCC) has evolved from being 
      predominantly cytokine-based to being grounded in the use of drugs targeting 
      vascular endothelial growth factor, platelet-derived growth factor and mammalian 
      target of rapamycin (mTOR) pathways. New agents including the small-molecule 
      targeted inhibitors sunitinib, sorafenib and temsirolimus and the monoclonal 
      antibody bevacizumab have shown anti-tumor efficacy and have become the standard 
      of care for most patients. Sunitinib and temsirolimus have shown significant 
      improvements in overall survival (OS), in the first-line setting, when compared 
      with interferon. Sorafenib has demonstrated prolonged progression-free survival 
      (PFS) in a phase III study in comparison with placebo in the second-line setting. 
      More recently, two phase III studies have compared bevacizumab and interferon 
      with interferon alone. Both studies showed a statistically significant 
      improvement in PFS for the combination arm but no difference in OS. Everolimus 
      showed prolonged PFS in the second/third-line setting. Pazopanib prolongs PFS in 
      naive/cytokine refractory patients. Immunotherapy confers a small but significant 
      OS advantage but only for the minority of patients with good prognostic features. 
      The results of these trials and ongoing efforts to improve treatment of MRCC are 
      the focus of this review.
CI  - Copyright 2010 S. Karger AG, Basel.
FAU - Di Lorenzo, Giuseppe
AU  - Di Lorenzo G
AD  - Medical Oncology, University Federico II, Naples, Italy.
FAU - Scagliarini, Sarah
AU  - Scagliarini S
FAU - Di Napoli, Marilena
AU  - Di Napoli M
FAU - Scognamiglio, Florinda
AU  - Scognamiglio F
FAU - Rizzo, Mimma
AU  - Rizzo M
FAU - Carteni', Giacomo
AU  - Carteni' G
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20100202
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biomarkers, Tumor/metabolism
MH  - Carcinoma, Renal Cell/*drug therapy/metabolism/secondary
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/metabolism/pathology
MH  - Prognosis
RF  - 58
EDAT- 2009/01/01 00:00
MHDA- 2010/03/24 06:00
CRDT- 2010/02/05 06:00
PHST- 2010/02/05 06:00 [entrez]
PHST- 2009/01/01 00:00 [pubmed]
PHST- 2010/03/24 06:00 [medline]
AID - 000258504 [pii]
AID - 10.1159/000258504 [doi]
PST - ppublish
SO  - Oncology. 2009;77 Suppl 1:122-31. doi: 10.1159/000258504. Epub 2010 Feb 2.